Loading…

Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial

Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twent...

Full description

Saved in:
Bibliographic Details
Published in:American journal of ophthalmology 2009-02, Vol.147 (2), p.291-297.e2
Main Authors: Maia, Otacilio O, Takahashi, Beatriz S, Costa, Rogerio A, Scott, Ingrid U, Takahashi, Walter Y
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3
cites cdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3
container_end_page 297.e2
container_issue 2
container_start_page 291
container_title American journal of ophthalmology
container_volume 147
creator Maia, Otacilio O
Takahashi, Beatriz S
Costa, Rogerio A
Scott, Ingrid U
Takahashi, Walter Y
description Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P < .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P < .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P < .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.
doi_str_mv 10.1016/j.ajo.2008.08.024
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66847761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002939408006673</els_id><sourcerecordid>66847761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</originalsourceid><addsrcrecordid>eNp9kt2K1DAUx4so7uzqA3gjAdG7jkmbSRoFQcZVF0ZWxvU6nKanmLFNxqQdmH0RX9fUKS7shXBIcsjvfOT8k2XPGF0yysTr3RJ2fllQWi0nK_iDbMEqqXJWKfYwW1BKi1yVip9l5zHukiskl4-zs3RfqHJVLLLfa9_X1mFDNhAxEHANuXJDgIMdAkJHboKF3ljnO--QtD6Qr8F3tsUAgz0g-WChxsEask2r83sYfhz_ZvkCZuwgkMsGe3hDrh3mR0z-FuPYDZH4lgDZJtL39jbVX3fWWTNX7J5kj1roIj6d94vs-8fLm_XnfHP96Wr9fpMbLviQoyxNY-qylWWhTG2gLmqkrF3Jkjd8Rat0ZqyBVq0kGCbpynCujJJKpEDalhfZq1PeffC_RoyD7m002HXg0I9RC1FxKQVL4It74M6PwaXeNGNlVQnGFU0UO1Em-BgDtnofbA_hqBnVk2Z6p5NmetJMT1bwFPN8zjzWPTZ3EbNICXg5AxDTgNoAztj4jysY45XgE_f2xGEa2MFi0NFYdAYbG9AMuvH2v228uxdtZkV-4hHj3Wt1LDTV36bPNf2tNGMqhCzLP0Z8ylY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1138861490</pqid></control><display><type>article</type><title>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</title><source>ScienceDirect Journals</source><creator>Maia, Otacilio O ; Takahashi, Beatriz S ; Costa, Rogerio A ; Scott, Ingrid U ; Takahashi, Walter Y</creator><creatorcontrib>Maia, Otacilio O ; Takahashi, Beatriz S ; Costa, Rogerio A ; Scott, Ingrid U ; Takahashi, Walter Y</creatorcontrib><description>Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P &lt; .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P &lt; .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P &lt; .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2008.08.024</identifier><identifier>PMID: 18929352</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Cataracts ; Clinical trials ; Colleges &amp; universities ; Combined Modality Therapy ; Diabetes Mellitus, Type 2 - complications ; Diabetes. Impaired glucose tolerance ; Diabetic retinopathy ; Diabetic Retinopathy - physiopathology ; Diabetic Retinopathy - therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Eye surgery ; Female ; Glucocorticoids - therapeutic use ; Glycated Hemoglobin A - analysis ; Hemorrhage ; Hospitals ; Humans ; Injections ; Laser Coagulation - methods ; Lasers ; Macular degeneration ; Macular Edema - physiopathology ; Macular Edema - therapy ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Nitric oxide ; Ophthalmology ; Retina - pathology ; Retinopathies ; Standard deviation ; Tomography, Optical Coherence ; Treatment Outcome ; Triamcinolone Acetonide - therapeutic use ; Visual Acuity - physiology ; Vitreous Body</subject><ispartof>American journal of ophthalmology, 2009-02, Vol.147 (2), p.291-297.e2</ispartof><rights>Elsevier Inc.</rights><rights>2009 Elsevier Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</citedby><cites>FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21148642$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18929352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maia, Otacilio O</creatorcontrib><creatorcontrib>Takahashi, Beatriz S</creatorcontrib><creatorcontrib>Costa, Rogerio A</creatorcontrib><creatorcontrib>Scott, Ingrid U</creatorcontrib><creatorcontrib>Takahashi, Walter Y</creatorcontrib><title>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P &lt; .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P &lt; .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P &lt; .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.</description><subject>Biological and medical sciences</subject><subject>Cataracts</subject><subject>Clinical trials</subject><subject>Colleges &amp; universities</subject><subject>Combined Modality Therapy</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - physiopathology</subject><subject>Diabetic Retinopathy - therapy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Eye surgery</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Hemorrhage</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Injections</subject><subject>Laser Coagulation - methods</subject><subject>Lasers</subject><subject>Macular degeneration</subject><subject>Macular Edema - physiopathology</subject><subject>Macular Edema - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Nitric oxide</subject><subject>Ophthalmology</subject><subject>Retina - pathology</subject><subject>Retinopathies</subject><subject>Standard deviation</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Triamcinolone Acetonide - therapeutic use</subject><subject>Visual Acuity - physiology</subject><subject>Vitreous Body</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kt2K1DAUx4so7uzqA3gjAdG7jkmbSRoFQcZVF0ZWxvU6nKanmLFNxqQdmH0RX9fUKS7shXBIcsjvfOT8k2XPGF0yysTr3RJ2fllQWi0nK_iDbMEqqXJWKfYwW1BKi1yVip9l5zHukiskl4-zs3RfqHJVLLLfa9_X1mFDNhAxEHANuXJDgIMdAkJHboKF3ljnO--QtD6Qr8F3tsUAgz0g-WChxsEask2r83sYfhz_ZvkCZuwgkMsGe3hDrh3mR0z-FuPYDZH4lgDZJtL39jbVX3fWWTNX7J5kj1roIj6d94vs-8fLm_XnfHP96Wr9fpMbLviQoyxNY-qylWWhTG2gLmqkrF3Jkjd8Rat0ZqyBVq0kGCbpynCujJJKpEDalhfZq1PeffC_RoyD7m002HXg0I9RC1FxKQVL4It74M6PwaXeNGNlVQnGFU0UO1Em-BgDtnofbA_hqBnVk2Z6p5NmetJMT1bwFPN8zjzWPTZ3EbNICXg5AxDTgNoAztj4jysY45XgE_f2xGEa2MFi0NFYdAYbG9AMuvH2v228uxdtZkV-4hHj3Wt1LDTV36bPNf2tNGMqhCzLP0Z8ylY</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Maia, Otacilio O</creator><creator>Takahashi, Beatriz S</creator><creator>Costa, Rogerio A</creator><creator>Scott, Ingrid U</creator><creator>Takahashi, Walter Y</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20090201</creationdate><title>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</title><author>Maia, Otacilio O ; Takahashi, Beatriz S ; Costa, Rogerio A ; Scott, Ingrid U ; Takahashi, Walter Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Cataracts</topic><topic>Clinical trials</topic><topic>Colleges &amp; universities</topic><topic>Combined Modality Therapy</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - physiopathology</topic><topic>Diabetic Retinopathy - therapy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Eye surgery</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Hemorrhage</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Injections</topic><topic>Laser Coagulation - methods</topic><topic>Lasers</topic><topic>Macular degeneration</topic><topic>Macular Edema - physiopathology</topic><topic>Macular Edema - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Nitric oxide</topic><topic>Ophthalmology</topic><topic>Retina - pathology</topic><topic>Retinopathies</topic><topic>Standard deviation</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Triamcinolone Acetonide - therapeutic use</topic><topic>Visual Acuity - physiology</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maia, Otacilio O</creatorcontrib><creatorcontrib>Takahashi, Beatriz S</creatorcontrib><creatorcontrib>Costa, Rogerio A</creatorcontrib><creatorcontrib>Scott, Ingrid U</creatorcontrib><creatorcontrib>Takahashi, Walter Y</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maia, Otacilio O</au><au>Takahashi, Beatriz S</au><au>Costa, Rogerio A</au><au>Scott, Ingrid U</au><au>Takahashi, Walter Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>147</volume><issue>2</issue><spage>291</spage><epage>297.e2</epage><pages>291-297.e2</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>Purpose To evaluate laser combined with intravitreal triamcinolone acetonide (IVTA) for the management of patients with proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME). Design Randomized clinical trial. Methods settings: Single center. study population: Twenty-two patients with bilateral treatment-naïve moderate PDR and CSME. intervention: Laser (panretinal and macular) photocoagulation was performed in each eye, followed by IVTA in one randomly assigned eye. Best-corrected visual acuity (BCVA), fundus photography, and optical coherence tomography were performed at baseline and at months 1, 3, 6, 9, and 12. main outcome measures: Changes in BCVA, central macular thickness (CMT), and total macular volume (TMV). Results The mean logarithm of the minimal angle of resolution (logMAR) BCVA improved significantly, and mean CMT and TMV were significantly reduced in the IVTA group compared with the laser-only group (controls) at all study follow-up visits ( P &lt; .001). The mean logMAR BCVA (Snellen equivalent) was 0.44 (20/50−2 ) for the IVTA group and 0.38 (20/50+1 ) for the controls at baseline, and 0.12 (20/25−1 ) for the IVTA group and 0.32 (20/40−1 ) for the controls at 12 months ( P &lt; .001). The mean CMT and TMV were, respectively, 360 μm and 8.59 mm 3 for the IVTA group and 331 μm and 8.44 mm 3 for the controls at baseline, and 236 μm and 7.32 mm 3 for the IVTA group and 266 μm and 7.78 mm 3 for the controls at 12 months ( P &lt; .001). Conclusions The combination of laser photocoagulation with IVTA was associated with improved BCVA and decreased CMT and TMV when compared with laser photocoagulation alone for the treatment of moderate PDR with CSME.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>18929352</pmid><doi>10.1016/j.ajo.2008.08.024</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9394
ispartof American journal of ophthalmology, 2009-02, Vol.147 (2), p.291-297.e2
issn 0002-9394
1879-1891
language eng
recordid cdi_proquest_miscellaneous_66847761
source ScienceDirect Journals
subjects Biological and medical sciences
Cataracts
Clinical trials
Colleges & universities
Combined Modality Therapy
Diabetes Mellitus, Type 2 - complications
Diabetes. Impaired glucose tolerance
Diabetic retinopathy
Diabetic Retinopathy - physiopathology
Diabetic Retinopathy - therapy
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Eye surgery
Female
Glucocorticoids - therapeutic use
Glycated Hemoglobin A - analysis
Hemorrhage
Hospitals
Humans
Injections
Laser Coagulation - methods
Lasers
Macular degeneration
Macular Edema - physiopathology
Macular Edema - therapy
Male
Medical sciences
Middle Aged
Miscellaneous
Nitric oxide
Ophthalmology
Retina - pathology
Retinopathies
Standard deviation
Tomography, Optical Coherence
Treatment Outcome
Triamcinolone Acetonide - therapeutic use
Visual Acuity - physiology
Vitreous Body
title Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A00%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Laser%20and%20Intravitreal%20Triamcinolone%20for%20Proliferative%20Diabetic%20Retinopathy%20and%20Macular%20Edema:%20One-year%20Results%20of%20a%20Randomized%20Clinical%20Trial&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Maia,%20Otacilio%20O&rft.date=2009-02-01&rft.volume=147&rft.issue=2&rft.spage=291&rft.epage=297.e2&rft.pages=291-297.e2&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2008.08.024&rft_dat=%3Cproquest_cross%3E66847761%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-e73cdcb3f7329cbcab2be01f5734d450801f11daf957ac1705c449c97963cd0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1138861490&rft_id=info:pmid/18929352&rfr_iscdi=true